Insulin Resistance - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Insulin Resistance - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Insulin Resistance - Pipeline Review, H1 2015', provides an overview of the Insulin Resistance's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Insulin Resistance
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Insulin Resistance
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Insulin Resistance Overview 8
Therapeutics Development 9
Pipeline Products for Insulin Resistance - Overview 9
Pipeline Products for Insulin Resistance - Comparative Analysis 10
Insulin Resistance - Therapeutics under Development by Companies 11
Insulin Resistance - Therapeutics under Investigation by Universities/Institutes 13
Insulin Resistance - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Insulin Resistance - Products under Development by Companies 16
Insulin Resistance - Products under Investigation by Universities/Institutes 17
Insulin Resistance - Companies Involved in Therapeutics Development 18
AUS Bio Limited 18
Genfit SA 19
GlaxoSmithKline plc 20
Hadasit Medical Research Services & Development Ltd 21
Mertiva AB 22
Mochida Pharmaceutical Co., Ltd. 23
Novartis AG 24
Prometheon Pharma, LLC 25
Sanofi 26
Thetis Pharmaceuticals LLC 27
Insulin Resistance - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
6860766 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BVS-857 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drugs to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Englerin A - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GFT-505 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MD-960 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PEG-Catalase - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptide for Obesity and Insulin Resistance - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SAR-088 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SERX-1 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule for Hypertension and Insulin Resistance - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule to Target AMPD2 for Hypertension and Metabolic Disorders - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
TP-113 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Insulin Resistance - Recent Pipeline Updates 60
Insulin Resistance - Dormant Projects 66
Insulin Resistance - Product Development Milestones 67
Featured News & Press Releases 67
Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables
Number of Products under Development for Insulin Resistance, H1 2015 9
Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Insulin Resistance - Pipeline by AUS Bio Limited, H1 2015 18
Insulin Resistance - Pipeline by Genfit SA, H1 2015 19
Insulin Resistance - Pipeline by GlaxoSmithKline plc, H1 2015 20
Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 21
Insulin Resistance - Pipeline by Mertiva AB, H1 2015 22
Insulin Resistance - Pipeline by Mochida Pharmaceutical Co., Ltd., H1 2015 23
Insulin Resistance - Pipeline by Novartis AG, H1 2015 24
Insulin Resistance - Pipeline by Prometheon Pharma, LLC, H1 2015 25
Insulin Resistance - Pipeline by Sanofi, H1 2015 26
Insulin Resistance - Pipeline by Thetis Pharmaceuticals LLC, H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Stage and Target, H1 2015 30
Number of Products by Stage and Mechanism of Action, H1 2015 32
Number of Products by Stage and Route of Administration, H1 2015 34
Number of Products by Stage and Molecule Type, H1 2015 36
Insulin Resistance Therapeutics - Recent Pipeline Updates, H1 2015 60
Insulin Resistance - Dormant Projects, H1 2015 66